First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...
REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...
HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...
Please provide your email address to receive an email when new articles are posted on . Janssen Biotech announced that the FDA has expanded the labeling provisions for Simponi Aria infusions in ...
Janssen announced the results of two Program of Ulcerative Colitis Research Studies Utilizing and Investigational Treatment clinical studies recently published in Gastroenterology. The studies ...
SIMPONI® Receives CHMP Positive Opinion For Treatment Of Polyarticular Juvenile Idiopathic Arthritis
LEIDEN, Netherlands, May 27, 2016 /PRNewswire/ -- Janssen Biologics B.V. (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results